Dr. Piperdi on Immunotherapy in Lung Cancer

Bilal Piperdi, MD
Published: Wednesday, Jan 15, 2014

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.

Piperdi says initial data on immunotherapy agents for lung cancer treatment is encouraging. In addition to responses, these agents seem to be improving long-term survival, even in refractory patients.

It remains to be seen how these agents will interact with standard treatments, including chemotherapy and radiation. However, Piperdi thinks combining immunotherapy agents with targeted agents is going to be the greatest area of interest and benefit over the next couple of years.

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.

Piperdi says initial data on immunotherapy agents for lung cancer treatment is encouraging. In addition to responses, these agents seem to be improving long-term survival, even in refractory patients.

It remains to be seen how these agents will interact with standard treatments, including chemotherapy and radiation. However, Piperdi thinks combining immunotherapy agents with targeted agents is going to be the greatest area of interest and benefit over the next couple of years.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x